Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-123290
Filing Date
2024-11-07
Accepted
2024-11-07 16:06:26
Documents
73
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q alxo-20240930.htm   iXBRL 10-Q 2458365
2 EX-10.1 alxo-ex10_1.htm EX-10.1 113562
3 EX-31.1 alxo-ex31_1.htm EX-31.1 17233
4 EX-31.2 alxo-ex31_2.htm EX-31.2 17435
5 EX-32.1 alxo-ex32_1.htm EX-32.1 9745
6 EX-32.2 alxo-ex32_2.htm EX-32.2 9759
  Complete submission text file 0000950170-24-123290.txt   8780797

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT alxo-20240930.xsd EX-101.SCH 1037309
75 EXTRACTED XBRL INSTANCE DOCUMENT alxo-20240930_htm.xml XML 1458622
Mailing Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-466-7125
ALX ONCOLOGY HOLDINGS INC (Filer) CIK: 0001810182 (see all company filings)

EIN.: 850642577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39386 | Film No.: 241435570
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)